Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.
To assess whether T1 relaxation time of tumors may be used to assess response to bevacizumab anti-angiogenic therapy.12 female nude mice bearing subcutaneous SKOV3ip1-LC ovarian tumors were administered bevacizumab (6.25ug/g, n=6) or PBS (control, n=6) therapy twice a week for two weeks. T1 maps of...
Main Authors: | Murali K Ravoori, Masato Nishimura, Sheela P Singh, Chunhua Lu, Lin Han, Brian P Hobbs, Sunila Pradeep, Hyun J Choi, James A Bankson, Anil K Sood, Vikas Kundra |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4476738?pdf=render |
Similar Items
-
In vivo magnetic resonance imaging of orthotopic prostate cancer
by: Murali K Ravoori, et al.
Published: (2020-07-01) -
New dual mode gadolinium nanoparticle contrast agent for magnetic resonance imaging.
by: Ketan B Ghaghada, et al.
Published: (2009-10-01) -
Visualizing the prostate gland by MR imaging in young and old mice.
by: Murali Ravoori, et al.
Published: (2013-01-01) -
The role of tumor microenvironment in resistance to anti-angiogenic therapy [version 1; referees: 2 approved]
by: Shaolin Ma, et al.
Published: (2018-03-01) -
Dynamic Modeling of the Angiogenic Switch and Its Inhibition by Bevacizumab
by: Dávid Csercsik, et al.
Published: (2019-01-01)